Latest News and Press Releases

See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to...

BELGRADE, Mont., April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...

BELGRADE, Mont., April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...

Core recurring revenue to increase 7% to 8% over first quarter 2015The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3...

BELGRADE, Mont., March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...

BELGRADE, Mont., March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its...

See footnote about the use of pro forma financial information Fourth Quarter 2015 Highlights: Consolidated total revenue increased 14.1% to a record $22.3 million compared to pro forma fourth...

BELGRADE, Mont., March 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...

BELGRADE, Mont., March 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...

BELGRADE, Mont., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading...